bromocriptine has been researched along with Parkinsonian Disorders in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, X; Mailman, RB; Yang, Y | 1 |
| Anand, L; Arora, V; Bhardwaj, A; Dhamija, RM; Jindal, A; Kumar, G; Sahney, A; Sarin, SK; Sharma, BC; Vijayaraghavan, R | 1 |
| Ganguly, A; Lee, D; Schultz, BJ; Wiemerslage, L | 1 |
| Cenci, MA; Lindgren, HS; Ohlin, KE | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Bido, S; Contado, C; Cortesi, R; Drechsler, M; Esposito, E; Mariani, P; Mazzoni, S; Menegatti, E; Morari, M; Ravani, L; Volta, M | 1 |
| Calne, DB; Greenacre, JK; Leigh, PN; Petrie, A; Reid, JL; Teychenne, PF | 1 |
| Asakawa, T; Ito-Yamashita, T; Namba, H; Sugiyama, K; Sun, W | 1 |
| Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Amaro, S; Gaig, C; Gómez-Choco, MJ; Martí, MJ; Tolosa, E | 1 |
| Au-Yeung, KM; Chan, KH; Cheng, TS; Cheung, RT; Ho, SL; Mak, W | 1 |
| Mohanasundari, M; Sabesan, M; Sethupathy, S; Srinivasan, MS | 1 |
| Colau, JC; Ha, DE; Legendre, G | 1 |
| Fukuzaki, K; Kamenosono, T; Nagata, R | 1 |
| Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A | 1 |
| Brannan, T; Prikhojan, A; Yahr, MD | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
1 review(s) available for bromocriptine and Parkinsonian Disorders
| Article | Year |
|---|---|
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Globus Pallidus; Humans; Indoles; Levodopa; Lewy Body Disease; Lisuride; Male; Mental Status Schedule; Neurosurgery; Parkinson Disease; Parkinsonian Disorders; Piribedil; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Stereotaxic Techniques; Supranuclear Palsy, Progressive; Surveys and Questionnaires; Thalamus | 2001 |
2 trial(s) available for bromocriptine and Parkinsonian Disorders
| Article | Year |
|---|---|
A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism.
Topics: Adult; Antiparkinson Agents; Bromocriptine; Double-Blind Method; Female; Humans; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome | 2019 |
The cardiovascular effects of bromocriptine in Parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Blood Pressure; Bromocriptine; Heart Rate; Humans; Middle Aged; Parkinsonian Disorders | 1976 |
16 other study(ies) available for bromocriptine and Parkinsonian Disorders
| Article | Year |
|---|---|
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2021 |
Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.
Topics: 1-Methyl-4-phenylpyridinium; Action Potentials; Animals; Animals, Genetically Modified; Bromocriptine; Cholinergic Neurons; Dopamine Agonists; Dopaminergic Neurons; Drosophila melanogaster; Drosophila Proteins; Female; GABAergic Neurons; Male; Nerve Degeneration; Parkinsonian Disorders; Primary Cell Culture; Quinpirole; Receptors, Dopamine D2 | 2013 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 2009 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Fractionation, Field Flow; Glycerides; Lipids; Male; Microscopy, Electron, Transmission; Nanoparticles; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Time Factors; X-Ray Diffraction | 2012 |
Behavioral performance at early (4 weeks) and later (6 months) stages in rats with unilateral medial forebrain bundle and striatal 6-hydroxydopamine lesions.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Bromocriptine; Corpus Striatum; Injections; Male; Medial Forebrain Bundle; Methamphetamine; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior | 2013 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders | 2002 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
Parkinsonism-hyperpyrexia syndrome not related to antiparkinsonian treatment withdrawal during the 2003 summer heat wave.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Dantrolene; Diagnosis, Differential; Female; Fever of Unknown Origin; Heat Stroke; Humans; Infections; Male; Muscle Relaxants, Central; Neuroleptic Malignant Syndrome; Parkinsonian Disorders | 2005 |
Wilson's disease with depression and parkinsonism.
Topics: Adult; Antiparkinson Agents; Brain; Bromocriptine; Chelating Agents; Depressive Disorder; Female; Hepatolenticular Degeneration; Humans; Magnetic Resonance Imaging; Parkinsonian Disorders; Penicillamine; Suicide, Attempted; Tomography, X-Ray Computed; Trientine; Trihexyphenidyl | 2005 |
Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Ataxia; Bromocriptine; Catalase; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Glutathione; Glutathione Peroxidase; Hand Strength; Hypericum; Lipid Peroxidation; Locomotion; Male; Mice; MPTP Poisoning; Muscle Weakness; Neuroprotective Agents; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Superoxide Dismutase | 2006 |
[Juvenile Parkinson's disease and recurring prematurity. Case report].
Topics: Adult; Antiparkinson Agents; Bromocriptine; Female; Humans; Infant, Newborn; Infant, Premature; Levodopa; Obstetric Labor, Premature; Parkinsonian Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2007 |
Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Catalepsy; Dopamine Agonists; Indoles; Macaca fascicularis; Male; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Reserpine; Tremor | 2000 |
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug Tolerance; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Rats; Rats, Sprague-Dawley; Rotation | 2000 |
Comparative effects of repeated administration of dopamine agonists on circling behavior in rats.
Topics: Animals; Benzothiazoles; Brain; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Administration Schedule; Ergolines; Indoles; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pergolide; Pramipexole; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Dopamine D1; Receptors, Dopamine D2; Thiazoles | 2000 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |